• Home
  • About Modra
    • Overview
    • Management Team
    • Supervisory Board
  • Technology
    • Oral Taxane Therapy
    • Patient Benefit
    • Publications
  • Pipeline
    • Overview
    • ModraDoc006/r
    • ModraPac005/r
    • Partnerships
  • Careers
  • News
    • Press Releases
    • Presentations
    • Events
  • Contact
Dizy-Logo

  • Modra Pharmaceuticals Presents Positive Phase IIb Results for ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer, at 2022 ASCO GU Annual Meeting

    17 February, 2022

  • Modra Pharmaceuticals Appoints Two New Supervisory Board Members Adding Significant Experience in Corporate and Clinical Development

    27 April, 2021

  • Modra Pharmaceuticals Presents Preliminary Data from Phase IIb Trial of ModraDoc006/r in Metastatic Prostate Cancer at 2021 ASCO GU Annual Meeting

    12 February, 2021

Follow Us

ModraDoc006/Ritonavir Offers Promising Therapeutic Option for mCRPC

11 February 2021

ModraDoc006/Ritonavir Offers Promising Therapeutic Option for mCRPC, Convenient Approach Amid COVID-19 Pandemic

Article published in ASCO Daily News, February 10 2021

Previous Post Modra Pharmaceuticals Announces First Patients Treated in Phase IIb Metastatic Prostate Cancer Trial
Next Post Modra Pharmaceuticals Presents Preliminary Data from Phase IIb Trial of ModraDoc006/r in Metastatic Prostate Cancer at 2021 ASCO GU Annual Meeting
Contact
Modra Pharmaceuticals B.V.
Barbara Strozzilaan 201
1083 HN Amsterdam
The Netherlands
Phone: +31 (0)20-205 0188
E-mail: info@modrapharmaceuticals.com
Info
  • Privacy Policy